DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C

DarioHealth Corp.

2022-Q2 EPS reported $1.43 revenue$14,242,000

Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).
Net loss $18.0M vs $17.8M in Q2 2021; operating loss $17.4M; cash $68M.
B2B2C contract value totals $55M; new national health plan deal providing reach to ~10M members.
Strategic decision to reduce DTC focus and prioritize B2B2C channels, cutting customer acquisition costs 70%.
Secured up to $50M non-dilutive credit facility with OrbiMed; on track to exceed 100 B2B2C contracts by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.